Steroids In Eosinophil Negative Asthma (SIENA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona College of Medicine
-
-
California
-
San Francisco, California, United States, 94143
- University of California at San Francisco
-
San Francisco, California, United States, 94143
- UCSF Benioff Children's Hospital
-
-
Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Health
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Nemours Children's Clinic
-
Orlando, Florida, United States, 32827
- Nemours Children's Clinic
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Chicago, Illinois, United States, 60611
- Northwestern Memorial Hospital
-
Chicago, Illinois, United States, 60614
- Ann and Robert H. Lurie Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
Saint Louis, Missouri, United States, 63110
- St. Louis Children's Hospital
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27110
- Duke University School of Medicine
-
Raleigh, North Carolina, United States, 27607
- North Carolina Clinical Research
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Rainbow Babies and Children's Hospital, Case Western Reserve University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, United States, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin-Madison
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physician-diagnosed asthma for at least previous 12 months.
- Able to perform reproducible spirometry.
- Baseline FEV1≥70% of predicted.
Asthma confirmed either by:
- Beta-agonist reversibility to 4 puffs albuterol ≥ 12% OR
- Methacholine PC20 ≤ 16 mg/ml
At least 1 of the following indications for chronic controller therapy:
- Asthma Symptoms > 2 days/week OR
- Nocturnal Asthma Symptoms > 2 nights/month OR
- Short-acting beta-agonist use for symptom control > 2 days/week
- For participants ≥18 years of age: Ability to provide informed consent. For participants under 18 years of age: Ability to provide verbal or written assent and ability of parent to provide informed consent.
- Willingness, if female and able to conceive, to utilize one medically-acceptable form of contraception.
Exclusion Criteria:
- Chronic inhaled or oral corticosteroid therapy.
- Use of inhaled or oral corticosteroid therapy within 6 weeks.
- New allergen immunotherapy within the past 3 months or anticipated changes to an ongoing immunotherapy regimen.
- Use of omalizumab within 3 months.
History of:
- bladder-neck obstruction, urinary retention or benign prostatic hyperplasia
- narrow angle glaucoma
- significant cardiovascular disorders and arrhythmias
- life-threatening asthma requiring treatment with intubation or mechanical ventilation within the past 5 years
- Respiratory tract infection within past 6 weeks.
- History of smoking within the past 1 year, or > 10 pack-years total if ≥ 18 years of age, or > 5 pack-years total if < 18 years of age.
- Chronic diseases or medical conditions (other than asthma) that could put the participant at risk by participation, e.g. chronic diseases of the lung (other than asthma), heart, liver, kidney, endocrine or nervous system, or immunodeficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Mometasone then Tiotropium then Placebo
Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
|
Mometasone is an ICS
Other Names:
Tiotropium is a LMA
|
|
EXPERIMENTAL: Mometasone then Placebo then Tiotropium
Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
|
Mometasone is an ICS
Other Names:
Tiotropium is a LMA
|
|
EXPERIMENTAL: Placebo then Mometasone then Tiotropium
Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
|
Mometasone is an ICS
Other Names:
Tiotropium is a LMA
|
|
EXPERIMENTAL: Placebo then Tiotropium then Mometasone
Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
|
Mometasone is an ICS
Other Names:
Tiotropium is a LMA
|
|
EXPERIMENTAL: Tiotropium then Placebo then Mometasone
Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
|
Mometasone is an ICS
Other Names:
Tiotropium is a LMA
|
|
EXPERIMENTAL: Tiotropium then Mometasone then Placebo
Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
|
Mometasone is an ICS
Other Names:
Tiotropium is a LMA
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1.
Time Frame: End of 12-week treatment period
|
This composite outcome uses a hierarchical method to ascertain differences in asthma control.
For each participant, treatments are first compared to see if they differ in terms of treatment failures.
If one treatment results in no treatment failures and another treatment does, it is deemed the superior treatment and no further comparisons are made.
If treatment superiority cannot be assigned by treatment failures, then they are compared by asthma control days (ACDs).
If one treatment yields at least 31 annualized ACDs more than another, it is deemed the superior treatment.
If treatment superiority still cannot be assigned by ACDs, then they are compared by percent predicted FEV1 at the end of a treatment period.
If one treatment yields at least 5% greater FEV1 than another, it is deemed the superior treatment.
If treatment superiority cannot be assigned by exacerbations, ACDs or FEV1, then that participant is classified as having no differential response.
|
End of 12-week treatment period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Failure
Time Frame: End of 12-week treatment period
|
Treatment Failure includes:
|
End of 12-week treatment period
|
|
Annualized Asthma Control Days
Time Frame: End of 12-week treatment period
|
Asthma Control Days (ACD) are based on patient completed electronic daily diaries, and are defined as: A day with no rescue albuterol use (pre-exercise albuterol will not be counted), no non-study asthma medications, no daytime asthma symptoms (shortness of breath, wheezing, chest tightness, phlegm/mucus rated as mild, moderate or severe, or cough rated as moderate or severe), no nighttime asthma symptoms, no unscheduled healthcare visits for asthma, and no PEF < 80% of predetermined baseline.
Annualized ACD are calculated as the proportion of ACD during the treatment period multiplied by 365.
|
End of 12-week treatment period
|
|
Forced Expiratory Volume at One Second (FEV1) Percent of Predicted
Time Frame: End of 12-week treatment period
|
FEV1, expressed as percent of predicted FEV1 based on age, sex, race, and height.
|
End of 12-week treatment period
|
|
Peak Expiratory Flow Rate
Time Frame: End of 12-week treatment period
|
Peak expiratory flow rate is a person's maximum speed of expiration.
It measures the airflow through the bronchi and thus the degree of obstruction in the airways.
|
End of 12-week treatment period
|
|
Asthma Exacerbations
Time Frame: End of 12-week treatment period
|
Asthma exacerbations are more severe episodes of acute worsening, defined by meeting one or more of the following:
|
End of 12-week treatment period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: William Busse, M.D., University of Wisconsin, Madison
Publications and helpful links
General Publications
- Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, Szefler SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet. Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19.
- Sorkness CA, King TS, Dyer AM, Chinchilli VM, Mauger DT, Krishnan JA, Blake K, Castro M, Covar R, Israel E, Kraft M, Lang JE, Lugogo N, Peters SP, Wechsler ME, Wenzel SE, Lazarus SC; National Heart Lung and Blood Institute's "AsthmaNet". Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era. Contemp Clin Trials. 2019 Feb;77:98-103. doi: 10.1016/j.cct.2018.12.012. Epub 2018 Dec 27.
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Anti-Inflammatory Agents
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Mometasone Furoate
- Tiotropium Bromide
Other Study ID Numbers
Other Study ID Numbers
- AsthmaNet 007
- 1U10HL098115 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.